Get ahead with in-depth pharmaceutical competitive intelligence
Stay on top of the rapidly changing competitive landscape with detailed insight and intelligence on key industry, commercial, clinical, regulatory, and R&D events.
Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our competitive and market intelligence can give you all the credible, detailed information you need in one place.
What we offer
You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.
Build detailed competitive and market landscape analyses quickly, with access to global information on:
How it helps
We help you more accurately:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
Key benefits:
Track and assess key events that will impact a drug’s probability of technical success and approval.
Key benefits:
Scrip
By Joseph Haas 14 Feb 2019
Gilead took a risky approach with selonsertib in NASH, pursuing a tough liver fibrosis benefit and failing, continuing a trend of disappointments outside of its antiviral franchises. Analysts don’t expect the second Phase III study in less-sick patients to succeed either.
Topic Drug review Drug approval Drug development landscape Clinical trials
Scrip
By John Davis 14 Feb 2019
Competing combination therapies may soon be battling for attention as first-line therapies for advanced or metastatic renal cell carcinoma, with Merck & Co being the latest big pharma to release more data on the Keytruda/Inlyta combo in the setting.
Topic Cancer
Scrip
07 Feb 2019
The Swiss major's pharma chief tells Scrip that its gene therapy for SMA offers much more than Biogen's Spinraza for both patients and payers, noting that the company is ready with alternative payment models for the pricey treatment as soon as approvals for Zolgensma are granted.
Topic Business strategies Drug approval Drug development landscape Drug review
Scrip
By Alexandra Shimmings 07 Feb 2019
Novartis may be turning up the rhetoric in spinal muscular atrophy as its cutting-edge gene therapy Zolgensma approaches a market currently enjoyed solely by Biogen’s Spinraza, but Roche is upbeat about the potential of its investigational oral product, risdiplam, to weigh in.
Topic Business strategies Drug approval Drug development landscape
Scrip
By Alexandra Shimmings 01 Feb 2019
Roche will highlight newer drugs as cancer blockbusters feel biosimilar pressure, while Celgene will talk to investors about its pending acquisition by Bristol. Novo Nordisk has faced concerns about generic and branded competition not to mention price pressures, but its longer-term outlook is sound; Merck's Keytruda tops investors' focus; Gilead looks ahead to new CEO O'Day.
Topic Biosimilars Business strategies Drug approval Drug development landscape Drug review
Scrip
By Jo Shorthouse 01 Feb 2019
As the EMA lowers the flags of the 28 EU nations that have flown outside its London offices for 24 years, and prepares to moves its HQ to the Netherlands, Scrip takes a look at Europe’s new pharma regulatory hub.
Topic Business strategies Brexit
Scrip
By Brian Yang 23 Jan 2019
As a promising market for orphan drugs, China has seen several approvals in this space in the past six months, mostly from multinationals. But Beijing-based CANbridge believes that a smaller biotech also has a good shot at a leadership role, despite a lack of funding and reimbursement and prickly pricing issues.
Scrip
By Jessica Merrill 23 Jan 2019
CEO Alex Gorsky highlighted growing public concern over US drug costs during J&J's Q4 earnings call, pressing for more transparency and value-based health care. The company's net drug prices declined more than 6% in 2018, he added.
Scrip
By Jung Won Shin 16 Jan 2019
2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.
Topic FDA Business strategies
Scrip
By Jessica Merrill 16 Jan 2019
Annual payment plans for gene therapies appear closer to becoming reality now that bluebird bio detailed plans at J.P. Morgan. Novartis, Sarepta and others are also talking to payers about alternative payment models. Harvard Pilgrim's Michael Sherman applauded the effort in an interview.
Datamonitor Healthcare
By Louisa Joseph 10 Jan 2019
The three urological cancers are undergoing tremendous changes in treatment practices as a result of new product launches and indication expansions.
Topic Cancer
Scrip
By Eleanor Malone 10 Jan 2019
Scrip journalists asked industry executives, consultants and analysts what they believe the big themes, trends and events will be in 2019. Here's what they told us about advances in therapeutic technologies and areas of clinical innovation.
Scrip
By Jessica Merrill 10 Jan 2019
News and notes from the 2019 J.P. Morgan Healthcare Conference. Pfizer CEO Bourla underscores need for scientific and commercial innovation, Gilead makes M&A a priority, Novartis' new R&D chief reflects on first meeting with CEO Narasimhan, Sarepta CEO Ingram clarifies regulatory path for micro-dystrophin, J.P. Morgan outlines deal and macro biopharma trends in 2019, and cell therapy panel discusses manufacturing challenges.
Datamonitor Healthcare
By Nicola Sawalhi-Leckenby 07 Jan 2019
Big changes are coming to the neuropathic pain market – are you prepared? Take a look at the projected neuropathic pain drug sales for the US, Japan, and five EU nations with the latest infographic from Datamonitor Healthcare. This snapshot view of the future of the neuropathic pain market is packed with data from the full Datamonitor Healthcare Neuropathic Pain Disease Coverage report.
Scrip
By Mike Ward 07 Jan 2019
Researchers from the MIT Laboratory for Financial Engineering, using clinical trials data provided by Informa Pharma Intelligence, have developed algorithms that provide a more timely, accurate and optimistic estimate of the risks and rewards of clinical trials.
Scrip
15 Feb 2019
Scrip
15 Feb 2019
Scrip
15 Feb 2019
Scrip
15 Feb 2019
Scrip
15 Feb 2019
Scrip
14 Feb 2019
Scrip
14 Feb 2019
Scrip
14 Feb 2019
Scrip
14 Feb 2019
Scrip
14 Feb 2019
Scrip
14 Feb 2019
Scrip
14 Feb 2019
Scrip
14 Feb 2019
Scrip
14 Feb 2019
Scrip
14 Feb 2019
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: